NEU neuren pharmaceuticals limited

6.69%

$14.20

I think you last point is something Jon is very conscious of and...

First 65 Last

Share
Profile

Follow
acowell

263 Posts.

18

13/12/24

01:30

Post #: 77027286
Share

Originally posted by Tony barber: ↑

I for one thought we'd be gone in February 2024.
I just figured that there's no way that a big pharma company will let this get away.

And the more I read, the more I note that big Pharma want late stage companies.
But I just still cant see how anyone would wait until a successful ph3.

I just dont know where the trigger point is now.
Is it an FDA agreement of endpoints and a structured beginning to a Ph3 trial?
We have the cash. So there's just no road blocks other than the endpoints being argued and agreed to.

I want the cash. But geez, there's families that are just waiting for these trials to get going. Because its going to be 4 years until they can get treatment after its started (if it passes).
That would be doing my head in as a parent.

Expand

I think you last point is something Jon is very conscious of and has stated this publically a number of times. Big pharma's ability to run parallel trials and increase speed to market worldwide is a big factor in decision making over next 12 months

NEU Price at posting: $13.24 Sentiment: Buy Disclosure: Held
17 Upvote

0 Great analysis

Reply

Top Stories

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

First 65 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $14.20		Change 0.890(6.69%)		Mkt cap ! $1.761B

Open	High	Low	Value	Volume
$13.50	$14.26	$12.96	$9.111M	655.8K

Buyers (Bids)

No.	Vol.	Price($)
1	2000	$14.17

Sellers (Offers)

Price($)	Vol.	No.
$14.23	3278	1

View Market Depth

No.	Vol.	Price($)
1	2000	14.170
2	1626	14.160
1	1000	14.100
2	2963	14.030
3	2000	14.000

Price($)	Vol.	No.
14.230	3278	1
14.250	2027	3
14.260	2920	1
14.270	1191	1
14.300	1163	2

Last trade - 16.15pm 27/06/2025 (20 minute delay)

NEU (ASX) Chart

I think you last point is something Jon is very conscious of and...

Monash IVF shares cater 25% – Disaster or deep-value play?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I think you last point is something Jon is very conscious of and...

Top Stories

Monash IVF shares cater 25% – Disaster or deep-value play?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News